key: cord-0847186-963w5qgp authors: Muller, Meredith S.; Chhetri, Srijana Bhattarai; Basham, Christopher; Rapp, Tyler; Lin, Feng-Chang; Lin, Kelly; Westreich, Daniel; Cerami, Carla; Juliano, Jonathan J.; Lin, Jessica T. title: Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings date: 2021-06-25 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115469 sha: c7338f117c17415c8ec73a502bc651decb65fe80 doc_id: 847186 cord_uid: 963w5qgp Alternatives to nasopharyngeal sampling are needed to increase capacity for SARS-CoV-2 testing. Among 275 participants, we piloted the collection of nasal mid-turbinate swabs amenable to self-testing, including polyester flocked swabs as well as 3D-printed plastic lattice swabs, placed into viral transport media or an RNA stabilization agent. Flocked nasal swabs identified 104/121 individuals who were PCR-positive for SARS-CoV-2 by nasopharyngeal sampling (sensitivity 87%, 95% CI 79-92%), missing those with low viral load (<10(6) viral copies/mL). 3D-printed nasal swabs showed similar sensitivity. When nasal swabs were placed directly into RNA preservative, the mean 1.4 log decrease in viral copies/uL compared to nasopharyngeal samples was reduced to <1 log, even when samples were left at room temperature for up to 7 days. We also evaluated pooling strategies that involved pooling specimens in the lab versus pooling swabs at the point of collection, finding both successfully detected samples with >10(5) viral copies/mL. Since the start of the SARS-CoV-2 pandemic, testing has been a cornerstone of the public health response. The de facto standard for clinical testing is PCR from nasopharyngeal (NP) swabs. However, nasopharyngeal sampling must be performed by trained staff using personal protective equipment (PPE). Shortages in both, as well as NP swabs themselves, often manifest when case counts climb. A wide array of strategies amenable to self-collection have been piloted to expand testing capacity, including the collection of nasal swabs, oropharyngeal and tongue swabs, saliva, and oral rinses [1] [2] [3] . The volume of tests conducted can also become burdensome and lengthen turnaround time, spurring interest in pooled testing strategies in low prevalence settings [4] [5] [6] [7] [8] . Finally, regarding sample storage and transport, viral specimens are typically placed in viral transport medium, and Centers for Disease Control and Prevention (CDC) recommends maintenance of cold chain prior to processing [1] , but this may not be possible in all settings. In order to implement a household transmission study in the early phases of the epidemic in North Carolina, when shortages of PPE and swabs were prevalent, we adopted a strategy of self-collected nasal swabs from household members during follow-up. Here we compare this strategy to concurrently collected nasopharyngeal swabs at enrollment in our study population. We piloted different types of swabs stored in different media. Given interest in pooling strategies for high throughput testing, we also used our cohort to test two different pooling strategies: pooling swabs at the point of collection or pooling sample lysate in the lab. Our findings provide confidence in using self-collected nasal swabs, preferably stored in an RNA stabilizer, when nasopharyngeal sampling is not feasible. Clinical samples were collected as part of a SARS-CoV-2 household transmission study conducted in the Piedmont region of North Carolina. The study received ethical approval from the Institutional Review Board at the University of North Carolina-Chapel Hill (UNC) and is registered at clinicaltrials.gov (NCT04445233). Participants were enrolled if they were adults that tested positive for SARS-CoV-2 by PCR at the UNC Respiratory Diagnostic Center and shared a living space with one or more persons who also agreed to participate. At enrollment, a standard clinician-collected nasopharyngeal (NP) swab was performed, followed by up to two other nasal swabs (on different sides) that were either collected by study staff or self-collected by the participant or their guardian with guidance from study staff (Figure 1 ). For nasal sampling, participants were instructed to insert the swab about 1-2 inches into one nostril , then swirl 5 times while slowly withdrawing the swab before placing it into the collection tube. All samples were placed into a cooler on ice prior to processing in a Biosafety level 2+ (BSL2+) laboratory space. and eluted in 20uL of water. We also evaluated the effect of storage media by collecting flocked NMT swabs directly into 3mL of 1X DNA/RNA Shield (Shield), with aliquots either frozen immediately upon return to the lab or left at room temperature for 4 or 7 days before being stored at -80°C. RNA was extracted from 100 uL of the lysate using the same extraction and elution protocols. Samples were tested using a CDC RT-qPCR protocol authorized for emergency use that consists of three unique assays: two targeting regions of the virus' nucleocapsid gene (N1, N2) and one targeting human RNase P gene (RP) (Catalog # 2019-nCoVEUA-01, Integrated DNA Technologies, IDT, Coraville IA) [9] . 5uL of extracted RNA was added to 15uL of each assay's reaction mixture containing TaqPath 1-Step RT-qPCR Master Mix, CG (Thermofisher Scientific Waltham MA) and the corresponding primer-probe set (IDT), followed by the recommended thermocycler protocol. Plasmid DNA containing the human RPP30 gene and SARS-CoV-2 in vitro transcribed RNA control (nCoVPC, IDT) were used as positive controls. Water was used as a negative extraction control. Samples were designated positive if all three PCRs were positive above the limit of detection (N1 and N2 for virus, RP for adequate sampling). If the N1 and N2 PCRs were negative, but the RP assay had a Ct value ≥30 or was negative, suggesting inadequate sampling, then the sample was re-extracted. The second result was reported if the RP Ct value was <30 or if both N1 and N2 PCRs were positive regardless of RP Ct value. The viral load of each sample, in copies/mL, was extrapolated from standard curves generated for each viral assay (N1 and N2) using serial dilutions of nCoVPC (range of 2,000 to 1 x 10 8 viral RNA copies/mL, Catalog # 10006625, IDT Coraville IA) on every qRT-PCR run performed (Table S1 ). The average copies/mL between the N1 and N2 assays was used as the final quantitative viral load. We note this viral load reflects copies per mL of extracted RNA. Based on our sample collection and RNA extraction volumes as well as volume of template RNA used in the RT-qPCR (5uL), this viral load represents the number of viral RNA copies per 5mL of VTM or Shield sample. The efficacy of pooling NMT samples was examined through two different approaches: pooling swabs at the point of care into the same collection vessel and pooling individual sample lysates prior to extraction. For the first strategy, self-collected 3D-printed lattice NMT swabs from each member of a household of three or more were collected and pooled together in 5mL of VTM. This was done at one or more of the study visits for each household. 200uL of the sample lysate was extracted and quantified as above. Results were compared to the self-collected individual flocked NMT swab collected at the same visit. In the second pooling strategy, one qRT-PCR positive sample lysate from a flocked NMT swab (pre-RNA extraction) was pooled with sample lysate from negative individuals to construct pool sizes of 5, 10, 15, and 20. The Ct values of twelve samples with viral copies/mL ranging from 10 4 to 10 10 were compared to the Ct values of their corresponding pools. A probit analysis of results from the nCoVPC plasmid control concentrations (ranging from 2,000 to 1 x 10 8 copies/mL as part of standard curves generated in every RT-qPCR run) by parametric curve fitting to hit rate data was used to determine the limit of detection (LOD) of the N1 and N2 qRT-PCR assays. Samples that were positive in both N1 and N2 assays, but with an average viral load that fell below the average LOD of N1 and N2 were categorized as indeterminate. The sensitivity and specificity of different swab types for RT-qPCR detection of SARS-CoV-2 was calculated using flocked NP swabs as the reference standard. Additionally, the difference in the quantitative viral load was compared for different collection strategies. Comparisons were made on the log scale and analyzed using Wilcoxon matched-pairs signed rank testing with a p-value <0.05 considered significant. Statistical analyses were performed using GraphPad Prism 8 and SAS 9.4 (Cary NC). We report data from 644 swab samples collected from 275 participants (91 households) at enrollment, 24 pools collected at follow-up or enrollment, and 44 pools constructed from participant samples in the lab. Participants ranged in age from 1-77 years old, with 71% >18 years of age. Probit analysis of nCoVPC plasmid control concentrations tested in 33 RT-qPCR runs yielded a limit of detection (LOD) for the N1 and N2 assays of 9,000 and 13,000 copies/mL, respectively ( Table S1 ). The average LOD between the two assays, 11,000 copies/mL, was used as the cutoff for sample positivity. A sample was deemed positive if the average viral load derived from the cycle threshold (Ct) values of N1 and N2 corresponded to a concentration ≥11,000 copies/mL, indeterminate if <11,000 copies/mL, and negative if either assay failed to amplify. Altogether (Figure 4A) . This was at least partly due to a sampling difference, as NMT swabs also showed on average 3.1 cycles higher Ct values in the human RP PCR (Figure S2) . Though the 3D-printed plastic lattice NMT swabs were more likely to lead to inadequate sampling, positive samples showed quantitative viral loads similar to flocked NMT swabs ( Figure 4A) . This was true despite on average 1. nasal swabs collected into VTM are shown using NP swabs with co-packaged universal viral transport system as the reference standard. Concordance of flocked vs. 3D nasal swabs is also shown. In (B), flocked NMT swabs were stored in Shield, and sample aliquots were directly frozen on day 1 (D1) or kept at room temperature before being stored at -80C on day 4 (D4) or day 7 (D7). Note that samples with indeterminate viral load (<11,000 copies/mL) were not included in the sensitivity/specificity analyses. (Figure 3) . Altogether, regardless of how many days the Shield samples were left out, the overall sensitivity was 85% (95% CI 77-92%). While sensitivity for detection was slightly diminished, quantitative viral loads derived from NMT Shield aliquots frozen on day 1 were comparable to NP viral loads (mean decrease of 0.5 log viral copies/mL (IQR -0.3-1.4), p=0.09) (Figure 4B ). For aliquots left at room temperature until day 4 and day 7, we observed a mean decrease that was still <1 log viral copies/mL compared to NP sampling (mean 0.8 and 0.8 log viral copies/mL, respectively (p=0.001 and p=0.0002) (Figure 4B ). The pooling strategies In a highly exposed outpatient cohort, we found nasal swabs to be reasonably sensitive, capturing 87% of SARS-CoV-2 infections diagnosed by nasopharyngeal sampling. This estimate is similar to most other outpatient studies showing >85% concordance between self-collected nasal swabs (either nasal mid-turbinate or anterior nasal swabs) and clinician-collected nasopharyngeal sampling [2, [10] [11] [12] [13] . Not all studies are consistent however, likely due to heterogeneity in testing environments, and inclusion of non-acute samples collected during follow-up [14, 15] . By calculating quantitative SARS-CoV-2 viral loads, our study gives clarity on where sensitivity is diminished [16] . For the majority of participants in which nasal sampling failed to detect virus, the NP viral load was <10 6 copies/mL (Ct>26), at a level that is less likely to be infectious [17] [18] [19] . Of these participants, 7/11 were antibody-positive (total Ig by ELISA [20] ) at the time of sampling (unpublished data), and for the 8/11 participants still reporting symptoms, the average duration of reported symptoms was 6.5 days. Thus, nasal samples are likely adequate for clinical diagnosis of acute infections to help expand testing capacity, but insensitivity to low viral load infections should be taken into consideration. On average, the decreased sensitivity of NMT swabs led to a little over a log decrease in viral copies/mL compared to NP swabs. Our pragmatic approach of "show one, then do one" meant that nasal swabs were both clinician and self-collected. Also, since we often collected two nasal swabs per person, one from each nostril, our sampling strategy may have slightly underperformed relative to other studies that sample both nostrils with the same swab. It should be noted that we tested flocked and 3D-printed lattice swabs, but did not test dry swabs or non-flocked cotton swabs. 3D-printed plastic swabs may also help address supply chain shortages [21, 22] . We first acquired prototype NMT lattice swabs from Resolution Medical in anticipation of shortage of supplies for our research study. In our limited testing, the prototype 3D-printed NMT lattice swabs showed high categorical concordance with NP swabs and also yielded similar viral loads compared to flocked NMT swabs. Similar high concordance has been demonstrated for 3Dprinted nasopharyngeal swabs [21] [22] [23] . Anecdotally, the prototype 3D-printed were observed to be more uncomfortable for study participants compared to flocked NMT swabs, a sentiment shared by other studies [21] . This may have contributed to the higher proportion of samples deemed as inadequate sampling. Labs also face VTM shortages requiring alternate transport media [24, 25] . Reagents which can inactivate virus and also keep samples stable at ambient temperature may be particularly apt substitutes [26] . We used 1x DNA/RNA shield (Zymogen), an RNA preservation agent that has been widely used to inactivate SARS-CoV-2 and other respiratory viruses in various sample types and is now part of saliva and NMT Shield collection kits that have received FDA emergency use authorization [https://www.zymoresearch.com/pages/shield-510k, [24] [25] . In our hands, storage of nasal swab samples in Shield did not improve their overall diagnostic sensitivity, but positive NMT swabs stored in Shield maintained quantitative viral loads more similar to those detected in concurrently collected NP swabs. Pooling specimens in the lab is a well-documented strategy to accelerate SARS-CoV-2 testing in high-throughput settings [4] [5] [6] . As in previous studies, we found that although Ct values do increase with pooling, the strategy can be broadly successful [27] [28] [29] [30] [31] . Samples with viral loads at or near the limit of detection [31] , or <10 6 viral copies/mL in the CDC Emergency Use Authorization assay we adopted, may go undetected as pool sizes increase. This was even more apparent when pooling swabs at the point of collection, which we piloted as unsupervised selfcollection of 3D-printed swabs into the same conical tube containing 5mL of VTM. Our findings add to the evidence base for nasal swabs as an adequate substitute for PCR-based clinical diagnosis of SARS-CoV-2 infection in outpatient settings where nasopharyngeal sampling is challenging. Viral recovery can be maintained even when immediate cold chain is not possible by storing swabs in an RNA preservation agent that also deactivates infectious virus. Combined with pooling specimens in the lab, these practical strategies can help expand testing in resource-constrained settings. 3D nasal swabs is also shown. In (B), flocked NMT swabs were stored in Shield, and sample aliquots were directly frozen on day 1 (D1) or kept at room temperature before being stored at -80C on day 4 (D4) or day 7 (D7). Note that samples with indeterminate viral load (<11,000 copies/mL) were not included in the sensitivity/specificity analyses. CDC. 2020. Information for Laboratories about Coronavirus Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing Unpublished Results. Selfcollected Saline Gargle Samples as an Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for COVID-19 Diagnosis in Outpatients Pooling of samples for testing for SARS-CoV-2 in asymptomatic people A pooled testing strategy for identifying SARS-CoV-2 at low prevalence Group Testing for Severe Acute Respiratory Syndrome-Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence Optimising SARS-CoV-2 pooled testing for low-resource settings Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2 for Disease Control C, Prevention, Others. 2020. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2 Evaluation of specimen types and saliva stabilization solutions for SARS-CoV-2 testing Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review Comparing Nasopharyngeal and Mid-Turbinate Nasal Swab Testing for the Identification of SARS-CoV-2 Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19 The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients Open Development and Clinical Validation of Multiple 3D-Printed Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19 Testing Bottleneck Low-Cost Polyester-Tipped Three-Dimensionally Printed Nasopharyngeal Swab for the Detection of Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) The Rapid Deployment of a 3D Printed Latticed Nasopharyngeal Swab for COVID-19 Testing Made Using Digital Light Synthesis Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR Evaluation of Saline, Phosphate-Buffered Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives Hebrew University-Hadassah COVID-19 Diagnosis Team. 2020. Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection Evaluation of COVID-19 RT-qPCR test in multisample pools Pooling of SARS-CoV-2 samples to increase molecular testing throughput A novel strategy for community screening of SARS-CoV-2 (COVID-19): Sample pooling method Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources AUTHOR CONTRIBUTIONS Writing -Original Draft, Visualization, Validation, Formal analysis, Investigation Srijana Chhetri: Writing-Reviewing and Editing, Validation, Investigation Christopher Basham: Project administration Tyler Rapp: Writing-Reviewing and Editing, Investigation Feng-Chang Lin: Writing-Reviewing and Editing, Formal analysis Kelly Lin: Writing-Reviewing and Editing Daniel Westreich: Writing-Reviewing and Editing Carla Cerami: Writing-Reviewing and Editing, Investigation Jonathan Juliano: Conceptualization, Writing-Reviewing and Editing Jessica Lin: Conceptualization, Supervision, Funding acquisition, Writing-Reviewing and Editing, Visualization, Investigation, Writing-Original Draft Samples stored in 1xShield were further analyzed via aliquots that were either immediately frozen (D1 Shield) or left out at room temperature for 4 or 7 days (D4 Shield, D7 Shield) before storage at -80°C. A total of 644 individual swabs were collected at enrollment, while 184 swabs were red stars Viral transport media from single positive samples with viral loads ranging from 10 4 to 10 10 were combined with negative samples to construct pool sizes of 5 Author Statement for Practical strategies for SARS-CoV-2 RT-PCR testing in resourceconstrained settings Writing -Original Draft, Visualization, Validation, Formal analysis, Investigation Srijana Chhetri: Writing-Reviewing and Editing Writing-Reviewing and Editing, Investigation Feng-Chang Lin: Writing-Reviewing and Editing, Formal analysis Kelly Lin: Writing-Reviewing and Editing Daniel Westreich: Writing-Reviewing and Editing Carla Cerami: Writing-Reviewing and Editing, Investigation Jonathan Juliano: Conceptualization, Writing-Reviewing and Editing Conceptualization, Supervision, Funding acquisition, Writing-Reviewing and Editing, Visualization, Investigation, Writing-Original Draft